Avastin in the first-line treatment of mCRC
Learn more about the trials providing key clinical data on Avastin in combination with chemotherapy in the first-line treatment of patients with mCRC
- AVF2107g.
- NO16966.
- BRiTE.
- First-BEAT.
Summary of Avastin first-line: consistent improvements in clinical benefit when continued until PD
Avastin provides clinical benefit when combined with first-line chemotherapy in patients with mCRC
In the pivotal phase III trial, AVF2107g, the addition of Avastin to IFL significantly improved
- Median OS(The time from trial entry to death from any cause) from 15.6 to 20.3 months - a 34% reduction in the risk of death.
- Median PFS(The time from trial entry to disease progression or death from any cause) from 6.2 to 10.6 months.
- ORR(The proportion of patients with defined tumour shrinkage; generally the sum of partial responses plus complete responses) from 34.8% to 44.8%.
In a subsequent phase III trial, NO16966, the addition of Avastin to XELOX or FOLFOX4 significantly improved median PFS from 8.0 to 9.4 months.
Data from community-based trials (First-BEAT and BRiTE) complement the data from phase III trials, indicating that Avastin provides clinical benefit when combined with a range of standard chemotherapy regimens. This benefit is achieved in a wide range of patient subgroups, including the elderly.
For maximum clinical benefit, Avastin treatment should be continued until PD.
Avastin in the second-line treatment of mCRC
Learn more about the E3200 trial, which investigated the efficacy(The capacity for beneficial change (or therapeutic effect) of a given intervention) of Avastin plus FOLFOX4 in the second-line treatment of patients with mCRC.
Summary of Avastin second-line: prolongs survival when combined with chemotherapy
Avastin provides a significant survival benefit when combined with second-line chemotherapy for the treatment of mCRC
In the second-line phase III trial, E3200, the addition of Avastin to FOLFOX4 significantly improved
- Median PFS from 4.7 to 7.3 months.
- Median OS from 10.8 to 12.9 months.
- ORR from 8.6% to 22.7%.
As in the first-line setting, Avastin should be continued until PD for maximum clinical benefit in patients who have received prior systemic therapy for metastatic(Pertaining to the spread of a disease, usually cancer, from one organ or part to another non-adjacent organ or part) disease.